Rockland Technimed, Ltd. is a Theranostics company, committed to the early diagnosis and treatment of hypoxic injury. Rockland's disruptive Nano-technology OxyFusion™ MRI medium enriched with its patented Oxy-17® process may set the new Gold standard of metabolic imaging.

Oxyfusion™ is a stable nano-emulsion of the FDA approved PFD, that can efficiently deliver ultra pure Oxygen-17 to target tissue at cellular level. Use of Oxyfusion™ will revolutionize the use of MRI for metabolic imaging, as it becomes the standard of care in clinical medicine.